AAP
IOVA icon

Aristotle Atlantic Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Aristotle Atlantic Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,218,025
Closed -$8.57M – 101
2023
Q2 		$8.57M Buy
1,218,025
+201,252
+20% +$1.44M 0.32% 65
2023
Q1 		$6.21M Buy
1,016,773
+8,337
+0.8% +$57.5K 0.32% 67
2022
Q4 		$6.44M Sell
1,008,436
-8,213
-0.8% -$64.1K 0.36% 66
2022
Q3 		$9.74M Buy
1,016,649
+5,840
+0.6% +$67.3K 0.59% 53
2022
Q2 		$11.2M Buy
1,010,809
+483,393
+92% +$6.33M 0.86% 32
2022
Q1 		$8.78M Buy
527,416
+1,878
+0.4% +$29K 0.54% 48
2021
Q4 		$10M Buy
+525,538
New +$11.6M 0.58% 42

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristotle Atlantic Partners's IOVA Position: Q3 2023 in Review

Aristotle Atlantic Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 1,218,025 shares — an estimated $8.57M sold.

Aristotle Atlantic Partners first reported a position in IOVA in Q4 2021 and held it in 7 quarters. The position peaked at $11.2M in Q2 2022. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • Aristotle Atlantic Partners reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Aristotle Atlantic Partners sold 1,218,025 Iovance Biotherapeutics shares in Q3 2023, an estimated $8.57M.
  • Aristotle Atlantic Partners first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 7 quarters.
  • Aristotle Atlantic Partners's Iovance Biotherapeutics position peaked at $11.2M in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on Aristotle Atlantic Partners's 13F filing for Q3 2023, filed 14 Nov 2023.